The Trump administration has secured a deal with Eli Lilly and Novo Nordisk to expand Medicare and Medicaid coverage for weight loss drugs and lower their prices. The agreement establishes a fixed price of $245 per month for these treatments across government programs and reduces copays for Medicare beneficiaries to $50. This policy shift aims to increase access to anti-obesity medications for millions of Americans, though specific eligibility details and implementation timelines are currently pending.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.